

December 2, 2013



DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com December 5th

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference

NEW YORK, Dec. 2, 2013 /PRNewswire/ --[DelMar Pharmaceuticals, Inc.](#) (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers.

DelMar's lead drug, VAL-083, is being developed in the U.S. to treat glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 is approved in China to treat chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and in the United States.

Event Information

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

DATE: December 5, 2013

TIME: 2:00 PM EST

LINK: www.retailinvestorconferences.com > click on the red "register / watch event now" button

It is recommended that investors pre-register to save time and receive event updates.

DelMar Pharmaceuticals Recent 2013 Highlights

- **November:** [Encouraging data from ongoing Phase 1/2 glioblastoma multiforme \(GBM\) clinical trial with VAL-083 presented at the Society of Neuro-Oncology \(SNO\) Annual Meeting](#)
- **October:** [DelMar presents data supporting VAL-083 as a potential treatment for three chemotherapy resistant cancers](#)
- **September:** DelMar establishes clinical advisory board to oversee new clinical studies in China
- **August:** FDA Allows Accelerated Dose-escalation for VAL-083 Clinical Trial in Glioblastoma

- **July:** VAL-083 Clinical Trial in Glioblastoma Expands to UC San Francisco (UCSF)
- **July:** DelMar and Guangxi Wuzhou Announce Chinese Government Funding Award
- **July:** First U.S. Patent Issued for VAL-083, Part of International IP Strategy

DelMar Is Developing Essential New Treatments For Aggressive Brain Cancers

DelMar is conducting a Phase 1/2 clinical trial to assess the safety and efficacy of VAL-083 as a potential new treatment for GBM patients who have failed standard therapies. Two weeks ago, DelMar reported encouraging interim results from the trial at the Society of Neuro-Oncology annual meeting ([press release](#)).

Fifty percent of patients with GBM will fail today's approved therapies, Temodal[®] and Avastin[®]. Tumor resistance to Temodar is well documented and known to be caused by the MGMT enzyme. Studies by the National Cancer Institute and DelMar have shown that VAL-083 acts through a unique mechanism unaffected by MGMT and has activity against a range of cancers.

Temodar generates more than US\$950 million annually in global revenues, primarily from the treatment of brain cancer.

In addition to its clinical activities in the U.S., DelMar has acquired the commercial rights to VAL-083 in China, where it is approved for chronic myelogenous leukemia (CML) and lung cancer. DelMar and its manufacturing partner, Guangxi Wuzhou Pharmaceuticals, plan to work with leading clinicians in China to develop new post-market data to support the sales and marketing of VAL-083 in these indications in China and to expand the market opportunities for the drug on a worldwide basis.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

SOURCE DelMar Pharmaceuticals, Inc.